Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
The trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM). Unlike the mixed isomer clomifene (Clomid), enclomiphene is the active anti-estrogenic component without the estrogenic zuclomiphene isomer. Studied as a treatment for secondary hypogonadism that preserves fertility, unlike exogenous testosterone.
A synthetic melanocortin receptor agonist derived from Melanotan II. Unlike Melanotan II, PT-141 was developed specifically for sexual dysfunction and received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Blocks estrogen receptors in the hypothalamus, removing negative feedback on GnRH release. This increases pulsatile GnRH secretion, which stimulates pituitary LH and FSH production, driving endogenous testosterone synthesis while maintaining spermatogenesis.
Activates melanocortin receptors (MC3R and MC4R) in the central nervous system, increasing sexual desire through a brain-based mechanism rather than vascular effects. This distinguishes it from PDE5 inhibitors like sildenafil which work peripherally.
- Secondary hypogonadism treatment
- Testosterone optimization without TRT
- Post-cycle therapy (PCT)
- Fertility preservation in hypogonadal men
- Alternative to clomiphene with fewer estrogenic side effects
- Female sexual dysfunction (FDA-approved indication)
- Male sexual dysfunction (off-label)
- Libido enhancement
- Erectile dysfunction (off-label)
- Headache
- Nausea
- Hot flashes
- Visual disturbances (less common than with clomiphene)
- Not FDA-approved — regulatory status uncertain
- Nausea (most common side effect — ~40% in trials)
- Flushing
- Headache
- Transient blood pressure increase
- Hyperpigmentation with repeated use
- Injection site reactions
Not FDA-approved. Repros Therapeutics (now Allergan) submitted NDA for Androxal but received a Complete Response Letter in 2015. Currently available through compounding pharmacies. Active interest from telehealth clinics as a TRT alternative.
FDA-approved as Vyleesi (bremelanotide injection) in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. Off-label use for male sexual dysfunction is common through telehealth clinics. Available through compounding pharmacies with prescription.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.